C19orf33在胰腺导管腺癌中的诊断及预后作用分析

The Role of C19orf33 in the Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinoma

目的:本研究旨在评估C19orf33表达在胰腺癌中的诊断和预后作用,进而为胰腺癌预后预测和指导诊疗提供新的位点。方法:从TCGA数据库和GEO数据库中筛选在胰腺癌中具有表达差异和临床预后意义的基因,得到C19orf33分子。采用Fisher确切概率法和χ^(2)检验比较C19orf33高、低表达组胰腺癌中各临床数据的差异。Cox比例风险回归分析验证C19orf33是否为胰腺癌生存预后的独立危险因子。结果:与低表达组相比,高表达C19orf33的胰腺癌患者的总生存率(OS,HR=2.01,95%CI:1.32-3.06,P<0.05)及无进展间期(PFI,HR=1.79,95%CI:1.21-2.64,P<0.05)明显降低,同时,ROC曲线分析也证实C19orf33基因能够准确区分胰腺癌不同疾病状态。结论:C19orf33不仅对胰腺癌患者的疾病状态具有诊断价值,而且是胰腺癌的独立预后危险因素。

Objective:The purpose of this study is to evaluate the diagnostic and prognostic value of c19orf33 gene expression in pancreatic cancer,so as to provide new ideas for the diagnosis,prognosis prediction and treatment target of pancreatic cancer.Methods:C19orf33 was obtained by screening genes with differential expression and clinical prognostic significance in pancreatic cancer from the TCGA database and Gene Expression Omnibus database.Chi square test and Fisher's exact test were used to compare the differences of clinical indicators between high and low expression groups of C19orf33.Cox regression analysis verified whether C19orf33 was an independent prognostic factor for pancreatic cancer.Results:Compared with patients of low expression of C19orf33,we found that the overall survival(OS,HR=2.01,95%CI:1.32-3.06,P=0.001)and progression free interval(PFI,HR=1.79,95%CI:1.21-2.64,P=0.003)of patients with high expression of C19orf33 were significantly lower.ROC curve analysis confirmed the predictive ability of C19orf33 expression in different disease states of pancreatic cancer.Conclusion:C19orf33 not only has diagnostic value for the disease status of patients with pancreatic cancer,but also is an independent prognostic risk factor for pancreatic cancer.